Prostate Cancer MDx Firm GenomeDx to Launch First Test This Year | GenomeWeb

NEW YORK (GenomeWeb News) – Seeking a share of a market estimated at around $1 billion, GenomeDx plans to launch its first test aimed at prostate cancer during the first half of this year, CEO Doug Dolginow said.

Based on whole-genome analysis to profile RNA expression signatures, the test measures the aggressiveness of prostate cancer in patients who have had a prostatectomy. Typically, after the surgery, a doctor will monitor a patient's prostate-specific antigen levels to evaluate whether the cancer has returned and whether follow-up treatment is needed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.